Duopharma likely to get a boost to sales

TA Research said Duopharma’s contract to supply pharmaceutical and non-pharmaceutical products to government hospitals and clinics has been extended for 12 months until end-2022.

PETALING JAYA: Duopharma Biotech Bhd’s sales are expected to be boosted once its RM375mil insulin supply contract to the Health Ministry is approved.

Duopharma and the government are still in the midst of clarifying certain terms of the proposed supply of insugen-insulin recombinant human formulations under the letter of award, according to TA Research.

“Once approved, Duopharma’s future sales will be boosted by the contract, which will span over three years until December 2024,” the research house said in its latest report.